ZTlido (lidocaine) Patch Won FDA Approval For The Treatment Of Postherpetic Neuralgia
FDA Approves Scilex Pharmaceuticals’s ZTlido (lidocaine) For The Treatment Of Postherpetic Neuralgia
Company: Scilex Pharmaceuticals, Inc.
Brand Name: ZTlido
Generic Name: lidocaine
Dosage Form: Patch
Previous Name: Ztilido
Treatment for: Postherpetic Neuralgia
General information about ZTlido
ZTlido (lidocaine topical system 1.8%) is a transdermal anesthetic formulation for the treatment of pain associated with post-herpetic neuralgia ("PHN"), a severe neuropathic pain condition.
ZTlido is a single-layered anhydrous patch featuring proprietary technology that offers advantages over the multi-layered hydrogel patches. Containing only 36 mg of lidocaine per patch, compared to the 700 mg found in the multi-layered hydrogel system, ZTlido 1.8% patches use a specialized construction that makes them thinner, more adhesive and more flexible, with a rate-controlling membrane designed for more effective lidocaine delivery.
